 The drug tested in this study is called Roflumilast. Roflumilast is being developed to treat people who have chronic obstructive pulmonary disease COPD. This study investigated the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate, pulmonary function, and major adverse cardiovascular events MACE in COPD patients who were concomitantly treated with a fixed combination of long-acting beta-agonists LABA and inhaled glucocorticosteroids. 